semaglutide trial design
5 Ways Researchers Read Secondary Outcomes Wrong About Semaglutide
Researchers misread secondary outcomes about semaglutide in five key ways, as illustrated by the 2% absolute difference in asthma events between tirzepatide and semaglutide. The marginal gap, despite a headline-grabbing relative risk reduction, sparked a broader critique of how trialists handle post-hoc signals. Understanding these errors is essential for clinicians